整理 | GLP1减重宝典内容团队在刚刚宣布合作开发长效GLP-1受体激动剂后,礼来(Eli Lilly)又达成了一项新的生物技术合作协议,进一步拓展其在减重治疗领域的影响力。此次,这家制药巨头与Juvena Therapeutics携手,拟通过高达6.5亿美元的里程碑支付,共同开发有助于维持肌肉质量与功能的新疗法。尽管财务细节尚未公开,协议包括一笔未披露的首付款、股权投资以及基于阶段性成果的激励...
Source Link整理 | GLP1减重宝典内容团队在刚刚宣布合作开发长效GLP-1受体激动剂后,礼来(Eli Lilly)又达成了一项新的生物技术合作协议,进一步拓展其在减重治疗领域的影响力。此次,这家制药巨头与Juvena Therapeutics携手,拟通过高达6.5亿美元的里程碑支付,共同开发有助于维持肌肉质量与功能的新疗法。尽管财务细节尚未公开,协议包括一笔未披露的首付款、股权投资以及基于阶段性成果的激励...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.